J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
This article was originally published in The Pink Sheet & The Rose Sheet
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.
You may also be interested in...
Sanofi sells US rights to anti-diarrhea Kaopectate brand to Arcadia Consumer Healthcare, which plans to invest in marketing and innovation behind the brand. Arcadia also markets the Nizoral dandruff shampoo and Fungi-Nail consumer health brands.
Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
UK-based Alliance Pharma reported a good year for its OTC business in 2018, while French players Boiron and Ipsen endured a more difficult 12 months.